In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

The US House of Representatives comprehensively voted in favour of the BIOSECURE Act, which will prohibit businesses in the US from contracting with various Chinese firms on national security grounds.

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move will ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Donald Trump. The company has indicated that it is ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC ...

A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...

Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...